Semaglutide vs tirzepatide: how I actually decide.

They're not the same medication.

This is worth stating clearly because the media often treats GLP-1 medications as interchangeable. They are not. They share a mechanism — both activate the GLP-1 receptor, which slows gastric emptying, reduces appetite, and improves glucose regulation. But tirzepatide also activates the GIP receptor, making it a dual agonist. That additional pathway appears to contribute to greater weight loss in head-to-head data and may produce a somewhat different metabolic profile. The dosing landscape has also evolved: semaglutide is now available at higher doses (Wegovy HD 7.2 mg, FDA-approved in 2026) in addition to the original formulations.

The weight loss data.

In clinical trials, tirzepatide produced greater average weight loss than semaglutide. Earlier data came from separate trials — SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide — which made direct comparison imprecise. That changed with SURMOUNT-5, a head-to-head trial that directly compared tirzepatide and semaglutide in adults with obesity without diabetes. At 72 weeks, tirzepatide produced approximately 20.2% mean body weight loss compared to 13.7% with semaglutide. That's a significant difference in a direct comparison. An important caveat: SURMOUNT-5 compared tirzepatide against semaglutide at doses up to 2.4 mg — not the newer 7.2 mg Wegovy HD dose approved in 2026. A head-to-head comparison at those higher semaglutide doses does not yet exist.

But trial data is population-level. Your individual response depends on your starting weight, your metabolic profile, your adherence, your diet and exercise, your genetics, and how your body processes the medication. Some patients respond dramatically to semaglutide and modestly to tirzepatide, and vice versa.

I don't treat population averages. I treat the patient in front of me.

The cardiovascular data.

Semaglutide currently has the stronger cardiovascular evidence. The SELECT trial — a large, randomized outcome trial — showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established cardiovascular disease. That's a significant finding and it's specific to semaglutide.

Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) was published in late 2025. The result: tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, but it did not demonstrate statistical superiority. That's a meaningful distinction. Semaglutide's SELECT data — a 20% MACE reduction in patients with obesity — remains the stronger cardiovascular evidence. For a patient with established cardiovascular disease or significant cardiovascular risk factors, that data is a meaningful factor in my prescribing decision.

How I actually choose.

In practice, the decision comes down to a few clinical considerations:

If cardiovascular risk is the primary concern

Semaglutide has the stronger cardiovascular outcome data. SURPASS-CVOT showed tirzepatide noninferior but not superior for MACE, while SELECT showed a clear 20% reduction. For a patient with a prior cardiac event, significant atherosclerotic disease, or a high cardiovascular risk profile, I lean toward semaglutide.

If maximum weight loss is the primary goal

The trial data favors tirzepatide for average weight loss. For a patient with a higher starting BMI who needs to lose a larger absolute amount of weight, tirzepatide may be the stronger option — assuming no contraindications and acceptable tolerability.

If GI tolerance is a concern

Both commonly cause gastrointestinal adverse effects, particularly during dose escalation. Individual tolerability varies. If a patient has had significant GI issues with one medication, switching to the other is reasonable.

If the patient has type 2 diabetes

Both medications improve glycemic control. Tirzepatide's dual mechanism may produce slightly greater HbA1c reductions, which could make it the preferred choice for a patient whose diabetes management is a co-equal goal alongside weight loss.

If cost or access is a factor

This is the reality of prescribing in 2026. Insurance coverage, manufacturer savings programs, pharmacy availability, and out-of-pocket cost differ between the two medications and change frequently. Sometimes the "best" medication is the one the patient can actually access and afford consistently. I help patients navigate this — it's part of the job.

One thing both medications have in common.

Neither semaglutide nor tirzepatide manages itself.

Whichever medication we choose, the rest of the work is the same: baseline lab evaluation, careful dose titration, muscle preservation strategy, side effect management, regular monitoring, and a long-term plan for what happens when you reach your goal weight.

The medication choice matters. But it's one variable in a much larger clinical equation. The physician managing the equation matters more.